Substituted quinazolines
US7910597B2 · kind B2 · utility
1Cited by
52References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2007 |
| Grant date | Mar 22, 2011 |
| Priority date | — |
| Expiry date | Jul 8, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the discovery of 3- and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.